Chief, Division of Medical Oncology, Keck School of Medicine of USC
Oncology
Dr. Darcy V. Spicer, MD
|
|
Give Review
Doctor Darcy V. Spicer, MD practices Oncology. Darcy Spicer is a published MD. He has 55 papers published. The most current publication "Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil." Darcy Spicer is registered with Medicare and accepts Medicare payments.
Publications
- Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation.
- Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young Women.
- Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.
- Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human Breast.
- Mammographic density changes during the menstrual cycle.
- Tamoxifen, soy, and lifestyle factors in Asian American women with breast Cancer.
- Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast Cancer.
- Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment.
- The detection of changes in mammographic densities.
- GRP78 as a novel predictor of responsiveness to chemotherapy in breast Cancer.
- Future possibilities in the prevention of breast Cancer: luteinizing hormone-releasing hormone agonists.
- Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast Cancer risk.
- Sex steroids and breast Cancer prevention.
- Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome.
- Gonadotropin hormone releasing hormone agonists [GnRHA] and prevention of familial breast Cancer.
- Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced Breast ...
- Estrogens, progestins, and risk of breast Cancer.
- Hormonal contraception and chemoprevention of female Cancers.
- The chemoprevention of breast Cancer by reducing sex steroid exposure: perspectives from epidemiology.
- GRP78 as potential predictor for breast Cancer response to adjuvant taxane therapy.
- Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics.
- Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast Cancer risk.
- Biological effects of green tea capsule supplementation in pre-surgery postmenopausal breast Cancer patients.
- Experiments on proliferation of normal human Breast tissue in nude mice do not show that progesterone does not stimulate Breast cells.
- The question of estrogen replacement therapy in patients with a prior diagnosis of breast Cancer.
- The endocrine prevention of breast Cancer.
- Estrogens, progestogens, normal breast cell proliferation, and breast Cancer risk.
- The prevention of breast Cancer through reduced ovarian steroid exposure.
- Breast Cancer prevention through modulation of endogenous hormones.
- Gonadotropin-releasing hormone agonist plus add-back sex steroids to reduce risk of breast Cancer.
- GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast Cancer.
- Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
- Breast Cancer screening and education in high risk women.
- Tamoxifen and prevention.
- Can mammographic densities predict effects of tamoxifen on the Breast?
- Progesterone concentrations--physiologic or pharmacologic?
- Contraception and Cancer prevention.
- Preoperative paclitaxel and radiotherapy for locally advanced breast Cancer: surgical aspects.
- Original p53 status predicts for pathological response in locally advanced breast Cancer patients treated preoperatively with continuous infusion 5-fluorouracil and ra...
- Hormone replacement after breast Cancer.
- Ovarian Cancer and long-term tamoxifen in premenopausal women.
- Tamoxifen and estrogen replacement therapy as agents of Disease prevention.
- Concurrent paclitaxel and radiation therapy for breast Cancer.
- Tamoxifen to prevent breast Cancer.
- Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast Cancer.
- Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic Breast carcinoma.
- Thymidylate synthetase inhibition in malignant tumors and normal Liver of patients given intravenous 5-fluorouracil.
- Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck Cancer.
- Preoperative 5-fluorouracil and radiation therapy for locally advanced breast Cancer.
- Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast Cancer.
- Preoperative concurrent paclitaxel-radiation in locally advanced breast Cancer: pathologic response correlates with five-year overall survival.
- Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
- Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast Cancer.
- Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone.
Schools
University of Calgary Faculty of Medicine
University Western Ontario Hospital
Montreal Genl Hospital McGill University
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Southern California - LAC+USC Medical Center -
University of Calgary Faculty of Medicine
Hospital
-
Keck Hospital of USC
Drug Facts
| NPI NUMBER | 1568407179 | |
| NPPES Provider LastName | SPICER | |
| NPPES Provider FirstName | DARCY | |
| NPPES Provider ZIPCode | 900890112 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 269.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 24.0 | |
| Percent Opioid Claims | 8.92 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1568407179 |
| Last Name Of The Provider | SPICER |
| First Name Of The Provider | DARCY |
| View All |
Similar Doctors
|
|
Dr. Mary E. Sehl, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heloisa P. Soares, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Becky J. Miller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John R. Daniels, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christy A. Russell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fairooz F. Kabbinavar, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Amir Goldkorn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barbara J. Gitlitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary M. Ichiuji, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacek K. Pinski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony B. El-Khoueiry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James S. Hu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Syma Iqbal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Breidi A. Calloway, NP |